Avadel Pharmaceuticals — Flamel Technologies — Investor Day (September 2016)
66 slides from Avadel Pharmaceuticals's investor day presentation, Sep 26, 2016
Slide 1: Investor & Analyst Day
@ FLAMEL technologies Investor & Analyst Day oa FLAMEL
Slide 2: Forward Looking Statements
Forward Looking Statements a FLAMEL This presentation may include “forward-looking statements” within the mecning of the Private Securities Utigation Reform Act of 1998, ail statements herein thet ove not clearly historical in nature ave forward-focking, and the words “anticipate,” “assume,” “believ
Slide 3: Flamel Research and Development Update
Flamel Research and Development Update David Monteith PhD, Vice President — Research and Development September 26, 2016 a FLAMEL
Slide 4: Presentation Outline
Presentation Outline * Flamel’s Proprietary Drug Delivery Platforms = Micropump LiquiTime Trigger Lock = Medusa * Once Nightly Sodium Oxybate = Product Profile = Studies Conducted To Date = Phase Ill Narcolepsy Trial — Status
Slide 5: Flamel's Proprietary Drug Delivery Platforms
Flamel’s Proprietary Drug Delivery Platforms Flamel’s Proprietary Drug Delivery Platforms Advanced Formulation and Delivery Platforms for Better and Safer Drugs Micropump* LiquiTime® Modes Corre Mosied/contlted Relea Soll al Druze Release of iid Oral Drags A FLAMEL CIES Medusa™ Trigger Lock” Modted/
Slide 6: Micropump
‘=a Micropump® «Drug Delivery Platform Modified/Controlled Release of Solid Oral Drugs
Slide 7: Micropump
Micropump® Micropump® allows development of modified and/or controlled release of solid, oral dosage formulations of drugs * Derivative LiquiTime® allows development of modified/controlled release of liquid formulations © Derivative Trigger Lock™ allows development of tamper-resistant modified/contr
Slide 8: Micropump Platform at a Glance
Micropump® Platform at a Glance * Extended/delayed release of drugs throughout Gl Tract * Precise pharmacokinetics of single or combination drugs in various formats * Numerous Micropump®-based products have been successfully tested in human clinical trials G rcial platform approved in and EU mbinati
Slide 9: Microparticles for Controlled/Modified Release
Microparticles for Controlled/Modified Release i Grane — Sevan oO ee alg code ea is ces ni Feb lahersinttheneen, Symi scm Bille + Microparticles dispersed in the stomach, pass into the small intestine where each microparticle releases drug at an adjustable rate over an extended period of time (up to
Slide 10: Micropump Key Benefits
Micropump® — Key Benefits * Extended release in the Gl tract up to 24 hours allowing plasma levels to be extended * Potentially improved efficacy (by extending therapeutic coverage) * Potentially reduced toxicity and/or side effects (by reducing Cmax or by reducing intra- and inter- patient varlabil
Slide 11: LiquiTime
ye LiquiTime® i Drug Delivery Platform Modified/Controlled Release of Liquid Oral Drugs oa FLAMEL September 26, 2016 fn
Slide 12: LiquiTime
LiquiTime® a FLAMEL * Allows development of modified/controlled release liquid formulations for patients having issues swall owing tablets/capsules * Not limited to working solely with ionic drugs as with resin-complex based technologies * Readily scalable to commercial quantities * Easy to swallow,
Slide 13: LiquiTime Key Benefits
LiquiTime® — Key Benefits * Easy to swallow, taste masked and good mouth feel + Applicable to wide range of drugs, not limited to ionic drugs as with resin-complex based technology * Combination of immediate release and extended release kinetics possible * Combination in the same formulation of diff
Slide 14: Update: Ibuprofen and Guaifenesin LiquiTime Products
Update: Ibuprofen and Guafenesin LiquiTime® Products * lbuprofen = 12 hour profile developed for pain/fever = Regulatory pathway deemed high risk and high cost * Guaifenesin = Successful pilot PK study reported in March 2015 = Second PK study ongoing = Update anticipated in early 2017 oa FLAMEL Sept
Slide 15: Trigger Lock
= Trigger Lock™ 2: Platform Abuse Deterrent Extended Release of Opioids
Slide 16: Trigger Lock for Abuse Deterrence
Trigger Lock™ for Abuse Deterrence + Drug loaded Micropump® microparticles Sustained Release (SR) microparticles individually polymer coated which are resistant to crushing + Viscosifying ingredient(s) To prevent abuse by injection after extraction in a small volume of solvent + Quenching ingredient
Slide 17: Abuse-Deterrence Category 1 Studies: in vitro Testing
Abuse-Deterrence Category | Studies: in vitro Testing Physical manipulation Route specific snorting Better Better + RT :Racrn Temperature = Trigger Lock™ has the potential to be more resistant to manipulation and abuse than formulations of opioids that are currently available. = Trigger Lock™ should
Slide 18: FT227 Clinical Development
FT227 Clinical Development = CLINICAL DEVELOPMENT Completed Ongoing + F127 studied in 30 healthy volunteers across Alcohol interaction stuty 2studies No safety or toleral ce Profile of Prototype 1 is consistent with the || PIND Meeting with FDA: WRO 55(D](2} pathway (Writing Response Oniy}: Bioequiv
Slide 19: Medusa
suas Medusa™ JM Drug Delivery Platform Modified/Controlled Release of Injectable Drugs & a FLAMEL September 26, 2016 19
Slide 20: In Vivo Drug Release from Medusa Depot
In Vivo Drug Release from Medusa™ Depot Release of the unmodified drug by diffusion, disaggregation of the depot Depot formation unesille : and competition with endogeneous proteins aver several days Injection Day Day x OQ om FE asanieais“S veorine 2 ieeniceds WN Wei Natural and sefe components disa
Slide 21: Phase Ib Outcome
Phase Ib Outcome a FLAMEL Safety of exenatide MPF excellent up to 4 weekly administrations of 140 mcg dose in 12 T2DM patients, 30 healthy volunteers administered with escalating doses up to 140 mcg The 1st administration leads to continuous release of exenatide observed over a period of 14 days wit
Slide 22: Once a Night Sodium Oxybate
Once a Night Sodium Oxybate (Extended Release Sodium Oxybate Granules for Oral Suspension)
Slide 23: Micropump
Micropump® Micropump® allows development of modified and/or controlled release of solid, oral dosage formulations of drugs * Derivative LiquiTime® allows development of modified/controlled release of liquid formulations © Derivative Trigger Lock™ allows development of tamper-resistant modified/contr
Slide 24: Once Nightly Sodium Oxybate
Once Nightly Sodium Oxybate Therapeutic target ‘Cataplexy and excessive daytime sleepiness in patients with narcolepsy Competitor xyrem® Technology? Micropump® Dosage (Once at night (2hrs after evening meal) Dosage Form Granules for oral suspension Strength 45g —6g-75g-98 Packaging Stick pack with c
Slide 25: FT218 Expected Dosing
4) FLAMEL FT218 Expected Dosing Xyrem® — 1" dose taken at bedtime — 2" dose on the nightstand to be taken 2.5 to 4 hours later FT218 Only one dose at bedtime! September 26, 2016
Slide 26: FT218 Advantages
FT218 Advantages Single Dose Nightly Formulation * Easier for patient (and partners} * Avoid waking up in the middle of the night and disruption of sleep + Avoid unattended dose available on nightstand © Avoid rising and moving in middle of the night (bathroorn, kitchen} * Lesswater / night compared
Slide 27: Summary of PK Data
Summary of PK Data + Extended Release Sodium Oxybate Granules for Oral Suspension has been studied in 40 healthy volunteers to date across 2 studies + Results of these studies at 4.5g show: ~ Expected onset of action similar to Xyrem® Y Crp, lower than the second dose of Xyrem® ¥ Comparable AUC on d
Slide 28: FT218 Project Progress to Date
FT218 — Project Progress to Date SS ¥ Successful Results from the First PK study with 3 prototypes ¥ Successful Results from 24 PK study with 2 prototypes and up to 7.5g ¥ Optimized formulation ¥ Phase Il protocol development and CRO selection v P-IND Meeting, ¥_ IND and SPA submission (March 2016)
Slide 29: FT218 Phase III Narcolepsy Trial Current Status
FT218 — Phase III Narcolepsy Trial Current Status a FLAMEL Phase Ill study designed and approved to start in US, Canada and several European countries Product scaled and available to start Phase Ill study 56 study sites selected and in various stages of readiness for trial initiation First web based
Slide 30: Narcolepsy Clinical Features
Narcolepsy Clinical Features Todd J. Swick, M.D. Assistant Clinical Professor, University of Texas Health Sciences Center, School of Medicine-Houston
Slide 31: Narcolepsy
Narcolepsy * Lifelong neurologic/sleep disorder characterized by the disruption of the boundaries between sleep and wake states * Classic pentad of signs and symptoms: = Excessive Daytime Sleepiness (EDS) Cataplexy Hypnogogic hallucinations Sleep paralysis Disrupted nighttime sleep (DNS) [nocturnal
Slide 32: Narcolepsy
Narcolepsy * Ancillary symptoms: = Automatic behavior " Loss of concentration and memory © Visual symptoms (blurred vision) + There are 2 distinct groups of patients with narcolepsy: = Those with cataplexy (Type 1 Narcolepsy as per ICSD-3 classification) «= Those without cataplexy (Type 2 Narcolepsy
Slide 33: Narcolepsy
Narcolepsy * Sleepiness is usually the first symptom = Defined as the irrepressible urge to sleep = Daytime lapses into sleep (sleep attacks) * Differential dx = Sleep deprivation = Obstructive Sleep Apnea = Narcolepsy Type 1 (with cataplexy) = Narcolepsy Type 2 (without cataplexy) = Idiopathic hype
Slide 34: Cataplexy
Cataplexy red consciousness lasting 4 Facial sagging + Episodic weakness without al k u Eyalide > se ~ Shatwtening seconds minutes and precipitated by excitement or panna y 4 Shire speeen + May occur several times/day or a few times/year 4 Weakness + Sagging of face, eyelid, or jaw; dysarthria (slur
Slide 35: Sleep Paralysis
Sleep Paralysis * The inability to move for a few seconds or minutes during sleep onset or offset * Often occurs in normal individuals on a relatively rare episodic basis but is far more common and almost universal in narcoleptics * Paralysis ends spontaneously (fear reaction is most common) or afte
Slide 36: Hypnogogic Hallucinations
Hypnogogic Hallucinations * Vivid, “waking dreams” that occur during transitions between sleep and wakefulness = Hypnogogic (occurring at sleep onset) = Hypnopompic (occurring upon awakening) * May accompany sleep paralysis or occur independently * May be tactile or auditory * Some awareness of surr
Slide 37: Narcolepsy-Age of Onset of Symptoms
Narcolepsy-Age of Onset of Symptoms * Onset between ages 15 and 30 in 60% of patients * Age range from 5 to 63 * Median age of 22 * Onset of cataplexy ages 9 to 68 * Hypnagogic hallucinations ages 9 to 65 * Sleep Paralysis ages 10 to 58 into lange po pustre of patie in Free a tes. Die oa FLAM Septem
Slide 38: Hypocretins (Orexins)
Hypocretins (Orexins) * Human narcolepsy/cataplexy (Type 1 Narcolepsy) is caused by loss of hypocretin (orexin) neurons in the dorsolateral hypothalamus (70,000 neurons in a paired set) * Thought to be caused by an autoimmune process directed specifically against hypocretin neurons in the hypothalam
Slide 39: Hypocretin Cell Loss as the Cause of Narcolepsy
Hert loss as Normal the cause of hypothalamus narcolepsy Abnormal structure i and severe » Normal loss of : % Hert Hert x s peptide peptide ‘ staining staining 5, a ( rt CPPS o € Hypocretin (Orexin) Cell Loss as the cause of narcolepsy vs. normal tissue A 2 FLAMEL September 26, 2016
Slide 40: Measuring Sleepiness as an Endpoint for Efficacy of EDS Treatment
Measuring Sleepiness as an Endpoint for Efficacy of EDS Treatment * Subjective scales = Stanford Sleepiness Scale = Epworth Sleepiness Scale * Objective Testing = Polysomnography/Multiple Sleep Latency Testing (PSG/MSLT) = Maintenance of Wakefulness Test (MWT) oa FLAMEL September 26, 2016
Slide 41: Classification of Narcolepsy
Classification of Narcolepsy * ICSD-3 (American Academy of Sleep Medicine-2014) = Narcolepsy Type 1 [Narcolepsy with Cataplexy] * Patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for >3 months * Cataplexy and a mean SOL of <8 min and >2 SOREMPs on an MS
Slide 42: Classification of Narcolepsy
Classification of Narcolepsy * ICSD-3 (American Academy of Sleep Medicine-2014) = Narcolepsy Type 2 [Narcolepsy without Cataplexy] (A/i criteria must be met) * Patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for >3 months * Mean SOL=<8 min and >2 SOREM
Slide 43: Incidence of Narcolepsy
Incidence of Narcolepsy * Data from the Mayo Clinic from (1960-1989) = Narcolepsy without cataplexy (1.37/100,000) = Narcolepsy with cataplexy (0.74/100,000) * Following 2010 (post H1N1 infection/immunization) there was a profound increase in the incidence of narcolepsy with cataplexy = Finland saw
Slide 44: Narcolepsy Management
Narcolepsy Management * Treatment of excessive daytime sleepiness (EDS) = Stimulants (methylphenidate, amphetamines) = modafinil (Provigil*)-racemic mixture of “r” and “s” forms of modafinil apne = armodafinil (Nuvigil*)-pure “r” isomer of modafinil * Treatment of Cataplexy = Tricyclic antidepressan
Slide 45: Goals of Treatment
Goals of Treatment * Reduce daytime sleepiness * Reduce/eliminate cataplexy * Control ancillary symptoms = Nightmares and unpleasant frequent dreams = Hallucinations = Sleep paralysis = Disturbed nocturnal sleep * Improve cognitive, psychosocial and work functioning * Improve safety of patient and p
Slide 46: Widespread Underdiagnosis of Narcolepsy
Widespread Underdiagnosis of Narcolepsy * Only 50,000 of the estimated 200,000 Americans with narcolepsy have been correctly diagnosed « Almost as common as Multiple Sclerosis * Can go 10 to 15 years after symptoms start before correct diagnosis is made * A patient with narcolepsy/cataplexy sees an
Slide 47: Challenges to Effective Treatment
Challenges to Effective Treatment SS * Under diagnosis and/or misdiagnosis of narcolepsy is VERY frequent = Daydreaming = Insomnia = Drug Abuse = Depression/Bipolar disorder = Apathy = ADD = Seizures * Insufficient exposure to patients with narcolepsy in sleep fellowships * Inadequate education of s
Slide 48: Challenges to Effective Treatment
Challenges to Effective Treatment * Too many “sleep physicians” are afraid to prescribe sodium oxybate « Myths about sodium oxybate = Health Care Practitioners think they are prescribing “GHB” = They think that sodium oxybate carries the same risks as GHB * Overdose/Coma + Addiction * Utility as a d
Slide 49: Treatment is Often Less than Effective
4) Treatment is Often Less than Effective + “Wake Up Narcolepsy” survey of pati 2017; data were analyzed of 1697 respondents along with information from their direct care + 2% wore between the ages of 25-58 + 78% had narcolepsy symptoms for Bears (porte diagrosis) +B tedcataplery + “Improved” EDS wi
Slide 50: Sodium Oxybate
Sodium Oxybate * Nat salt of gamma hydroxybuterate (GHB) * Only drug to be FDA approved to treat both excessive daytime sleepiness and cataplexy in patients with narcolepsy * % life 30-60 min * Allow at least 2 hours after eating to time of first dose * Nocturnal dosing (as a split dose) = of the fu
Slide 51: Sodium Oxybate
Sodium Oxybate * Increases slow wave sleep * Decreases time to sleep onset and decreases wakefulness after sleep onset « Needs to be titrated upwards over 4-8 weeks (max total nightly dose=9 gm) * Cannot be used with other CNS depressants or alcohol a FLAMEL eptember 26 2016 st
Slide 52: Sodium Oxybate
Sodium Oxybate * Issues related to split night dosing = Need to prepare both doses before bedtime (time consuming and increases the potential for dosing errors) = Proportion of patients who miss the second dose either because they can’t wake up with an alarm or who sleep through the alarm = Ina coll
Slide 53: Thomas Roth
Thomas Roth Sleep Disorders and Research Center Henry Ford Hospital September 26, 2016 53 :
Slide 54: REST-ON Trial
REST-ON Trial A Double blind, Randomized, Placebo Controlled, Two Arm Mutti- center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Extended Release Sodium Oxybate Granules for Orai Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subject
Slide 55: Study Objectives
Study Objectives * Primary objectives: = To compare efficacy of 6.0, 7.5 and 9.0 g of FT218 to placebo in treating EDS in both NT1 and NT2 subjects as measured by mean sleep latency on the Maintenance of Wakefulness Test (MWT) and by the Clinical Global Impression (CGI) rating of sleepiness = To com
Slide 56: Creating an Efficient Protocol
Creating an Efficient Protocol * No placebo group for stimulant. Very big issue * In majority of sites 16-18 ( prime age for narcolepsy onset ) will be included * Doses evaluated in crossover design not parallel group * Major efforts in recruitment and retention
Slide 57: Unique Efficient Study Design
Unique Efficient Study Design * Only two groups, one active one placebo, thus overall fewer subjects needed * Dose is studied within active group with all receiving 6, 7.5 and 9 grams * Duration of treatment for any given dose is therefore less * Screening period is carried out over time with extens
Slide 58: Inclusion Criteria
Inclusion Criteria * For NT1 only, current continuing presence of cataplexy as defined by subject report for the last 3 months * Subjects may use concomitant stimulants, but must comply with the following: = They must be on a stable dose of stimulants for at least 3 weeks prior to starting the scree
Slide 59: Study Population
Study Population * 264 study subjects, randomized across approximately 60 centers in USA, Canada, Europe * Subjects randomized 1:1 (NT1/NT2, single parallel group design) « Minimum 107 subjects for each arm will have both EDS and cataplexy September 26, 2016 59 :
Slide 60: Site Selection
Site Selection * Sites selected from United States, Europe and Canada * Total 56 sites: 31 US, 25 non US * Sites selected which had extensive experience in Narcolepsy and Narcolepsy Clinical Trails * Major Academic Narcolepsy Sites Participating France - Montpellier Italy — Bologna Neurology institu
Slide 61: Regulatory Approvals
Regulatory Approvals * United States * Canada * Virtually all EU sites September 26, 2016 62 :
Slide 62: Rest-ON Global Study Specific Recruitment Methods
Rest-ON Global Study Specific Recruitment Methods Flamel has established a robust subject recruitment and retention framework. Establishment of a study specific Patient Advisory Group mediated via the Narcolepsy Network. Inaugural PAG Meeting Hosted by Flame April 2016: ¥ Provide insight into patien
Slide 63: Rest-ON Global Study Specific Recruitment Methods
a FLAMEL Rest-ON Global Study Specific Recruitment Methods Social Media Campaign ¥ _Link2Trials focused social media campaign service for subject recruitment and retention: Y Country specific web-site Y Subjects directed to site (via social media campaign etc.) where interested subjects complete an
Slide 64: What Narcolepsy Patients Want
What Narcolepsy Patients Want * Summarizing the results from a patient survey with 1350 responses in preparation for the FDA meeting + “Adrug that would provide consistent and adequate control of the daytime sleepiness without the hard crash and one that would require 1 dose taken at bedtime resulti
Slide 65: Potential Advantages for Patients
Potential Advantages for Patients * Convenience * Nodisturbance of sleep for second dose « Less water intake * Potential greater efficacy with decreased risk of missing second dose * Greater safety
Slide 66: Potential Safety Differences
Potential Safety Differences * No unattended doses on night stand (concern with children in house or roommates) * Not arising during night thereby decreasing risk of fall accidents or amnestic episodes * Performance including driving at 6 hours post bed time * Less Suppression of arousal response at